جست‌وجوی استاد و پژوهشگر

Tamara Isakovaمشاهده پروفایل

استاد

• Chronic kidney disease
• Disordered mineral metabolism
• Diabetic nephropathy
• +۵ مورد دیگر

Tamara Isakova, MD, MMSc , is the Fowler McCormick Professor of Nephrology and Professor of Medicine (Nephrology and Hypertension) at Northwestern University Feinberg School of Medicine. She concurrently serves as Chief of Nephrology and Hypertension in the Department of Medicine and as Director of the Institute for Public Health and Medicine (IPHAM) Center for Translational Metabolism and Health. Dr. Isakova is affiliated with the Feinberg Cardiovascular and Renal Research Institute and the Northwestern University Clinical and Translational Sciences Institute (NUCATS). Education & Training MD: SUNY-Downstate Medical Center (2003) MMSc: Harvard Medical School (2009) Intern: Massachusetts General Hospital, Medicine (2004) Resident: Massachusetts General Hospital, Medicine (2006) Fellow: Massachusetts General Hospital & Brigham and Women’s Hospital, Nephrology (2010) Board Certified: Nephrology, American Board of Internal Medicine Research Focus Dr. Isakova’s translational program centers on disordered mineral metabolism in chronic kidney disease (CKD), integrating large-scale epidemiologic cohorts, randomized clinical trials, biomarker discovery, and patient-centered outcomes. Her work elucidates pathways linking FGF23, phosphate, vitamin D metabolites, and novel gut-derived factors to cardiovascular and renal endpoints. She leads the NIH-funded TRIDENT study, a multi-center cohort designed to redefine diabetic nephropathy through molecular phenotyping of kidney biopsies, and she heads the Chronic Kidney Disease Research Biorepository that supports biomarker validation across the translational continuum. Clinical Trials & Grants Principal Investigator, Transformative Research in Diabetic Nephropathy (TRIDENT) – NIH multi-site prospective cohort (NCT02986984) Principal Investigator, Chronic Kidney Disease Research Biorepository – repository and outcomes study (IRB STU00201546) Co-Investigator, O’Brien Kidney Center grant – Northwestern received $5.8 million NIH award to expand kidney disease prevention research Scientific Honors & Awards Elected Member, American Society for Clinical Investigation (2025) Elected Member, Association of American Physicians (2025) Department of Medicine Mentor of the Year (2021) Distinguished Mentor Award, American Society of Nephrology (2019) Feinberg School of Medicine Mentor of the Year (2019) Jack W. Coburn Endowed Lectureship, ASN Kidney Week (2017) Leadership & Service Dr. Isakova chairs or sits on multiple NIH and international data-safety monitoring boards, serves on the KDIGO Controversies Conference steering committee, and is Co-Chair of the ASN Kidney Week 2024 Program Committee. She is a Section Editor for Current Opinion in Nephrology and Hypertension and has held editorial roles with American Journal of Kidney Diseases and CJASN .

• Osteoarthritis
• Rheumatology
• Clinical Research
• +۶ مورد دیگر

Professor David Hunter is the Florance and Cope Chair of Rheumatology and Co-Director of the Sydney Musculoskeletal Health Flagship at the University of Sydney. He is a leading clinician-researcher in osteoarthritis (OA), with over 600 peer-reviewed publications and recognition as the world’s top OA expert on Expertscape (2014–current). His work spans clinical and translational research, focusing on OA epidemiology, imaging, novel therapies, and chronic disease management systems. Co-Director, Sydney Musculoskeletal Health Flagship Editor-in-Chief, Osteoarthritis and Cartilage Section Editor, UpToDate Osteoarthritis Academic Affiliation: University of Sydney, Kolling Institute Research Interests : Professor Hunter’s research emphasizes improving OA understanding and patient quality of life. Key areas include: Epidemiology of osteoarthritis Imaging (MRI, ultrasound) for structural and functional analysis Novel therapeutic interventions (e.g., platelet-rich plasma, disease-modifying drugs) Health service delivery for chronic disease Patient-reported outcomes in clinical trials Genetic and environmental risk factors for OA progression Biomechanics and hip/knee joint dynamics Article Trends : His recent work explores OA through clinical trials, imaging biomarkers, and health service innovations. Notable themes include: Virtual endpoints for knee replacement outcomes Diet and exercise interventions for overweight OA patients Comparative effectiveness of surgical vs. non-surgical therapies Role of muscle quality and radiomics in OA development Psychosocial factors in pain management Global OA guidelines and patient-centric care Scientific Awards : OARSI Clinical Researcher Award (2019) Vice-Chancellor’s Award for Research Excellence (2019) Distinguished Professorial Achievement Award, University of Sydney (2014) World-leading OA expert, Expertscape (2014–current) Advising and Grants : He supervises multiple PhD students working on OA-related projects, including: Medical and allied health practitioner concordance in OA management Factors affecting discharge after hip/knee arthroplasty Pentosan Polysulfate Sodium trials for knee OA Communication frameworks for OA empowerment His grants address cost-effectiveness of OA interventions, digital health tools, and multidisciplinary care programs, reflecting his commitment to translating research into clinical practice. Labs and Teams : He leads the osteoarthritis team at the Kolling Institute, collaborating with Sydney Musculoskeletal Health Flagship. His team specializes in: Osteoarthritis clinical trials MRI and ultrasound biomarker analysis Health service delivery optimization Global OA guideline development

• Reproductive Physiology
• Reproductive Toxicology
• Developmental Toxicology
• +۳ مورد دیگر

Tisha King Heiden is a Professor in the Department of Biology at the University of Wisconsin-La Crosse, specializing in reproductive physiology, reproductive toxicology, and developmental toxicology using fish models to investigate environmental contaminants. She serves on the International Joint Commission Health Professionals Advisory Board and holds active grants from the Freshwater Collaborative of Wisconsin. Her educational background includes: PhD, University of Wisconsin-Milwaukee Great Lakes WATER Institute (2005) MS, University of North Carolina - Greensboro (1998) BS, University of Wisconsin - Stevens Point (1996) Professor King-Heiden's research examines how pesticides, PFAS, triclosan, and heavy metals affect embryonic development, neurobehavior, and reproductive outcomes in zebrafish and fathead minnows. Her work bridges toxicology, endocrinology, and environmental science to address aquatic ecosystem risks and potential human health implications. Current projects focus on PFAS 'forever chemicals' and neonicotinoid insecticides, emphasizing real-world exposure scenarios and ecological relevance. Recent publications (2022-2024) reveal strong emphasis on contaminant mixtures, behavioral endpoints, and transgenerational effects. Her studies frequently demonstrate how sublethal exposures impair critical functions like foraging, survival, and reproductive fitness—providing data for regulatory risk assessments. Collaborations span multiple UW System institutions and address pressing issues like 'forever chemicals' in freshwater systems. Scientific recognition includes: Prairie Springs Environmental Leadership Award for faculty Top 5 Exceptional Paper in Environmental Toxicology and Chemistry (2014) Professor King-Heiden actively mentors students through hands-on research, with 28 documented advisees across publications. She secured two major Freshwater Collaborative grants: a five-year teaching initiative building water-career pipelines and a PFAS toxicity research project supporting student stipends. Her lab provides training in advanced toxicology methods while tackling urgent environmental challenges. Her research group integrates field and laboratory approaches to study contaminant impacts, preparing students for careers in environmental science through grant-funded projects and collaborative networks across Wisconsin's freshwater research community.

Anthony Otleyمشاهده پروفایل

استاد

• Pediatric Gastroenterology
• Inflammatory Bowel Disease
• Clinical Trials
• +۶ مورد دیگر

Dr. Anthony Otley is a Professor in the Department of Pediatrics and Department of Medicine at Dalhousie University's Faculty of Medicine. He serves as Associate Chair of Research for Pediatrics and Division Head of Pediatric Gastroenterology & Nutrition. Based at the IWK Health Centre in Halifax, Nova Scotia, Dr. Otley leads the Maritime Intestinal Research Alliance (MIRA) and holds key roles in national research networks including the CHILD-CIHR Canadian pediatric IBD Network and the IMAGINE SPOR Network. His research focuses on pediatric inflammatory bowel disease, with special emphasis on clinical trials methodology, development of patient-reported outcome measures, and the use of enteral nutrition for Crohn's disease management. Dr. Otley has made significant contributions to understanding the gut microbiome's role in pediatric IBD and has pioneered patient engagement approaches to set research priorities in this field. Dr. Otley's publication record demonstrates consistent contributions to high-impact journals in gastroenterology, immunology, and microbiology. His work spans clinical trials methodology, patient-reported outcomes development, microbiome research, and implementation science for nutritional therapies in pediatric IBD. 2015, Outstanding Physician of the Year – Inaugural recipient from Crohn's and Colitis Canada 2011, Award for Excellence in Patient and Family-Centered Care from IWK Health Centre 2004-2009, Clinical Research Scholar Award from Dalhousie University As a clinician-researcher, Dr. Otley maintains active clinical practice in pediatric gastroenterology while leading multiple research initiatives. His international work as a MicroResearch Mentor in Kenya and Uganda demonstrates his commitment to global health. His patient-centered research approach has been recognized by CIHR as part of their Faces of Health Research series, highlighting how he incorporates patient perspectives to guide research priorities in pediatric IBD. Dr. Otley leads the Maritime Intestinal Research Alliance (MIRA), which brings together a multidisciplinary team focused on gastroenterology research, treatment, and care using a model that values patient engagement, knowledge translation, scientific integrity, and innovation.

Peter Doshiمشاهده پروفایل

دانشیار

• Drug approval process
• Clinical trial transparency
• Evidence synthesis
• +۳ مورد دیگر

Peter Doshi is an associate professor of pharmaceutical health services research at the University of Maryland School of Pharmacy and a senior editor at The BMJ. Based in Baltimore, his academic work focuses on the drug approval process, risk-benefit assessment of medical products, and improving the credibility of evidence synthesis. He leads the Restoring Invisible and Abandoned Trials (RIAT) Support Center, which addresses publication bias and reporting bias in clinical trials. Dr. Doshi's educational background spans multiple disciplines, reflecting his interdisciplinary approach to pharmaceutical research: A.B. in Anthropology from Brown University A.M. in East Asian Studies from Harvard University Ph.D. in History, Anthropology, and Science, Technology and Society from MIT Fellowship in Comparative Effectiveness Research at Johns Hopkins University His research interests center on pharmaceutical regulation, clinical trial transparency, and evidence-based medicine. Dr. Doshi has been particularly active in examining the science and politics of influenza policy and has published extensively on neuraminidase inhibitors for influenza. More recently, he has focused on transparency issues in COVID-19 vaccine trials, advocating for greater access to raw trial data and raising methodological questions about vaccine efficacy assessments. His work often bridges historical, anthropological, and scientific perspectives to critically examine pharmaceutical evidence generation. Dr. Doshi has received significant recognition for his work, including: New Investigator Award from the American Association of Colleges of Pharmacy (2015) Selection for The Wired 'Smart List' (2013) Feature in The New York Times for work on clinical trial data access (2013) As principal investigator, Dr. Doshi has secured substantial grant funding, including a $1.4 million grant from Arnold Ventures (2017-2022) for the RIAT Support Center and a current $253,243 grant from Arnold Ventures for evaluating and improving consent in clinical trials. His publications reveal a consistent focus on methodological rigor and transparency across pharmaceutical research domains, with recent work critically examining vaccine trial design, data interpretation, and regulatory processes. Dr. Doshi maintains an active role in shaping discourse around pharmaceutical regulation, regularly presenting to bodies like the Institute of Medicine and serving on advisory panels to the European Medicines Agency. His dual role as academic researcher and senior editor at The BMJ creates a unique platform for influencing both research practices and scientific communication in the pharmaceutical field.

Michal Juraskaمشاهده پروفایل

پژوهشگر

• Biostatistics
• Vaccine Development
• Clinical Trials
• +۵ مورد دیگر

Michal Juraska, PhD, MS is a Senior Staff Scientist in the Gilbert Lab within the Biostatistics, Bioinformatics and Epidemiology Program of the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center. As a biostatistician, he engages in statistical and clinical trial methods research focused on vaccine science for HIV, COVID-19, malaria, dengue, and other diseases. He serves as a faculty member of the HIV Vaccine Trials Network (HVTN) and the COVID-19 Prevention Network (CoVPN), where he has served as a lead statistician on numerous vaccine and monoclonal antibody efficacy trials. His educational background includes: University of Washington, 2012, PhD (Biostatistics) University of Washington, 2009, MS (Biostatistics) Charles University in Prague, 2007, MS (Mathematical Statistics) Dr. Juraska's research spans multiple critical areas in vaccine science, with particular expertise in sieve analysis of breakthrough pathogen features and statistical evaluation of immune biomarkers as correlates of vaccine protection. His work has significantly advanced clinical immunobridging strategies aimed at securing vaccine licensure based on immunological surrogate endpoints when clinical outcomes are unavailable. He specializes in developing statistical frameworks to analyze how pathogen genetic features influence vaccine efficacy across diverse disease contexts. Analysis of his recent publications reveals a consistent focus on pathogen sequence-dependent vaccine efficacy across HIV, COVID-19, and malaria. His statistical approaches for evaluating how viral genetic variation impacts protection have become increasingly sophisticated, with recent work integrating machine learning techniques to predict vaccine efficacy based on pathogen sequence features. This methodology has important implications for vaccine design, regulatory approval pathways, and understanding immune escape mechanisms. Dr. Juraska actively mentors students, interns, and early-career statisticians, and teaches specialized workshops on statistical and computational tools for sieve and immune correlates analyses. His grant-supported work primarily involves leadership roles in major collaborative networks including HVTN and CoVPN, where he serves on data monitoring committees and leads statistical reporting for pivotal efficacy trials. Within Fred Hutch, he contributes to the Gilbert Lab's mission of developing innovative statistical methods for infectious disease prevention. His collaborative approach connects biostatisticians with laboratory scientists and clinicians to address critical questions in vaccine development, particularly regarding correlates of protection and methods for evaluating vaccine efficacy against genetically diverse pathogens.

Brice Maxime Hugues Ozenneمشاهده پروفایل

دانشیار

• Biostatistics
• Statistical Modeling
• Repeated Measurements Analysis
• +۶ مورد دیگر

Brice Maxime Hugues Ozenne is an Associate Professor in the Department of Public Health, Section of Biostatistics at the University of Copenhagen's Faculty of Health and Medical Sciences. He holds a shared position between the Section of Biostatistics at the University of Copenhagen and the Neurobiology Research Unit at Rigshospitalet. His work spans methodological research, software development for R, statistical consultations, and teaching. Dr. Ozenne's educational background includes: Ph.D. in Biostatistics from University Lyon 1, Lyon, France (2012-2015) with thesis on "Statistical modelling for the prognosis of stroke patients" Master's Degree in Biostatistics from University Lyon (2011-2012), completed as a double degree with École Centrale de Lyon Engineering Diploma from École Centrale de Lyon (2009-2012) Course in teaching and learning in higher education from UNIVERSITETPÆDAGOGIKUM (2022-2023) His primary research interests focus on statistical models for handling repeated measurements that arise in medical images, psychological questionnaires, and longitudinal studies. He specializes in developing Latent Variable Models and mixed models for neuro-imaging data, with particular attention to small sample size issues and multiple testing corrections. Additionally, he develops methods for assessing treatment effects in registry data, accounting for confounding, right-censoring, competing risks, and time-varying effects. His side projects include benefit-risk assessment using Generalized Pairwise Comparisons and planning/analyzing sequential trials with pipeline data. Dr. Ozenne's research output demonstrates strong interdisciplinary collaboration, particularly in neuroscience, psychiatry, and clinical research. His work frequently addresses methodological challenges in neuroimaging studies, antidepressant treatment evaluation, and registry-based epidemiological research. Recent publications show a consistent focus on serotonin receptor binding, treatment effects in depression, and advanced statistical methodologies for complex data structures. His scientific contributions have garnered significant attention, with publications picked up by 55 news outlets, blogged by 3 sources, reddited by 1 user, and referenced across various social media platforms including X (Twitter) and Bluesky. As an educator, Dr. Ozenne teaches: Ph.D. courses: Statistical analysis of repeated measurements and clustered data; Epidemiological methods in medical research (as course leader); Basic statistics MSc courses: Survival analysis for students in Statistics and Mathematics-Economics He previously served as a Post-Doc in biostatistics (2015-2020) with a shared position between the University of Copenhagen (researcher and teacher at the Graduate School of Health and Medical Sciences) and Copenhagen University Hospital (consultant and leader of the data analysis workpackage of the Neuropharm project). Dr. Ozenne's work is supported in part by a grant from Novo Nordisk A/S, which covers part of his salary during July 2025 - December 2026.

Thomas M. Habermannمشاهده پروفایل

استاد

• Lymphoma
• Hematologic Malignancies
• Leukemia
• +۳ مورد دیگر

Thomas M. Habermann, M.D., is a distinguished Professor of Medicine at Mayo Clinic College of Medicine and Science in Rochester, Minnesota, where he specializes in Hematology within the Mayo Clinic Comprehensive Cancer Center. With over three decades of experience, Dr. Habermann has established himself as a leading expert in lymphoma research and treatment, particularly in B-cell lymphomas, hairy cell leukemia, and post-transplant lymphoproliferative disorders. Dr. Habermann completed his medical training at Creighton University, earning both his undergraduate degree in Biology (1975) and his MD (1979), followed by residency and fellowship training at Mayo Clinic. He is board certified in Internal Medicine and Hematology and holds a master's faculty privilege in Clinical and Translational Science. His research interests focus on malignant lymphomas, with significant contributions to understanding lymphoma classification, prognostic factors, and treatment outcomes. Analysis of his extensive publication record reveals a strong emphasis on translating molecular findings into clinical practice, particularly regarding lymphoma subtypes and their therapeutic implications. Henry S. Plummer Distinguished Physician Award 2012 Lifetime Achievement for Outstanding Contributions to Medical Education Award Mayo Clinic Distinguished Educator Award Multiple Teacher of the Year awards from the Mayo Fellows Association Minnesota Hope Award from the Lymphoma Research Foundation As an educator, Dr. Habermann has held numerous leadership positions including education program director, head of section, associate chair of education in the Division of Hematology, and associate dean of internal medicine and medical subspecialties. His commitment to medical education has been recognized through multiple teaching awards throughout his career. He remains an active contributor to the field through his ongoing research, clinical practice, and participation in major professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and Lymphoma Research Foundation.

• Stroke research
• Cognitive decline and dementia
• Anticholinergic burden
• +۵ مورد دیگر

Martin Taylor-Rowan is a Research Fellow at the University of Glasgow's College of Medical, Veterinary & Life Sciences, School of Medicine, Dentistry & Nursing. His primary affiliation is with the Evidence Synthesis Group at the Complex Reviews Support Unit (CRSU), where he conducts research focused on stroke outcomes, cognitive decline, and geriatric assessment tools. Dr. Taylor-Rowan's research interests center on the intersection of stroke medicine and cognitive aging. His work investigates how physical and brain frailty impact stroke outcomes, develops patient-reported measures for treatment burden assessment after stroke (including the PETS-Stroke instrument), and examines anticholinergic burden as a risk factor for cognitive decline. He makes significant contributions to systematic review methodology and European Stroke Organisation guidelines. His publication record shows a strong focus on high-impact systematic reviews and clinical guidelines, with recent work emphasizing patient-centered outcome measures in stroke rehabilitation. Dr. Taylor-Rowan frequently collaborates with Professor Terence J. Quinn and contributes to major multicenter studies examining delirium, frailty, and cognitive outcomes in older stroke patients. Dr. Taylor-Rowan currently holds active research funding through the National Institute for Health and Care Research (NIHR153934) from 2023-2028, supporting his work in evidence synthesis for stroke and geriatric medicine. His research program involves multiple international collaborations and contributes directly to clinical guideline development through the European Stroke Organisation. His work with the Evidence Synthesis Group at CRSU positions him at the forefront of methodological innovation in evidence-based stroke medicine, with particular emphasis on translating research findings into practical clinical tools for assessing treatment burden and cognitive outcomes in stroke survivors.

• Aquaculture
• Fish Physiology
• Mucosal Immunology
• +۵ مورد دیگر

Professor Kristina Sundell is a leading researcher at the University of Gothenburg's Department of Biology and Environmental Sciences within the Faculty of Science. Her work bridges fundamental fish physiology with applied sustainable aquaculture solutions, addressing critical industry challenges through innovative scientific approaches. Her research focuses on aquaculture physiology , mucosal immunology , and sustainable feed development . Key areas include: Fish stress response mechanisms and welfare assessment Gut health and mucosal barrier function Valorization of side streams for novel feed ingredients Physiological adaptations of novel aquaculture species Sustainable nitrogen management in recirculating systems Analysis of her 15 most recent publications (2021-2025) reveals a strong trend toward circular economy applications in aquaculture, with 60% focusing on waste valorization and sustainable alternatives to traditional feed components. Her work increasingly integrates microbiome analysis with physiological endpoints, demonstrating a systems approach to aquaculture challenges. Professor Sundell maintains active collaborations across multiple departments at University of Gothenburg and with international institutions. Her research group employs diverse methodologies including physiological challenge tests, molecular analysis of mucosal barriers, and innovative feed trials. Current projects focus on developing sustainable alternatives to fishmeal through seaweed, insect, and microbial protein sources, while maintaining rigorous welfare standards for cultured species. Her laboratory work demonstrates strong practical applications for the aquaculture industry, particularly in developing circular economy solutions that convert waste streams into valuable resources while maintaining fish health and welfare.

• Interventional Radiology
• Interventional Oncology
• Vascular Radiology
• +۵ مورد دیگر

William S. Rilling, MD, FSIR is a Professor and Vice Chair of Clinical Operations for Image Guided Procedures in the Department of Radiology at the Medical College of Wisconsin. He specializes in Vascular and Interventional Radiology with a focus on interventional oncology, particularly liver-directed therapies for primary and metastatic liver cancers. Dr. Rilling serves as a member of the Cancer Center and maintains clinical privileges across multiple institutions including Froedtert Hospital, Zablocki VA Medical Center, Children's Hospital of Wisconsin, and other Froedtert Health system hospitals. Dr. Rilling's educational background includes a BS in Biochemistry from the University of Wisconsin-Madison (1986) and an MD from the University of Wisconsin-Madison School of Medicine (1990). He completed his Diagnostic Radiology residency at the Medical College of Wisconsin (1991-1995) and a Vascular & Interventional Radiology fellowship at Northwestern Memorial Hospital (1995-1996). His academic career progressed from Assistant Professor (1996-2000) to Associate Professor (2000-2006) to Professor (2006-Present) in both Radiology and Surgery (Surgical Oncology). Dr. Rilling's research focuses on advancing interventional oncology techniques, particularly in liver cancer treatment. Key areas include radioembolization with Y-90 microspheres, transarterial chemoembolization (TACE), microwave ablation, and image-guided tumor therapies. His recent work centers on the ACCLAIM trial investigating real-time 3D confirmation of ablation margins for colorectal liver metastases. He has made significant contributions to consensus guidelines for tumor ablation endpoints and quality of life considerations in interventional oncology procedures. His publication record spans over two decades with numerous high-impact studies in leading journals. Distinguished Faculty Member Award, Society of Cardiovascular and Interventional Radiology (2001) Designation of Fellow (FSIR), Society of Interventional Radiology (2003) Best Doctors in America recognition (2003) Thomas L. Smallwood Award for Patient Care Excellence (2013) Clinical Abstract of the Year Award, Society of Interventional Radiology (2015) Lee A. Biblo, MD Excellence in Professionalism Award (2019) Society of Interventional Radiology 2023 Charles T. Dotter Lecture Teacher of the Year, Vascular & Interventional Radiology Fellowship (2022-2023) As an educator, Dr. Rilling directed fellowship programs for over a decade and has been a Guest Examiner for the American Board of Radiology since 2002. His leadership extends to professional societies where he served as President of the Society of Interventional Oncology (2019-2020) and has held multiple committee roles with the Society of Interventional Radiology spanning over 25 years. He continues to actively shape the field through his research, mentorship, and leadership in advancing interventional oncology standards and practices.

Joseph J Finsمشاهده پروفایل

استاد

• Medical Ethics
• Bioethics
• Neuroethics
• +۵ مورد دیگر

Joseph J Fins, M.D., M.A.C.P., F.R.C.P., is a Professor at Weill Cornell Medicine in the Division of Medical Ethics in New York City. With 473 publications and 47,740 reads on ResearchGate, Dr. Fins is a leading scholar in medical ethics, neuroethics, and disorders of consciousness research. His educational background includes medical training reflected in his M.D. credential, along with professional certifications as indicated by M.A.C.P. (Master of the American College of Physicians) and F.R.C.P. (Fellow of the Royal College of Physicians). Dr. Fins's research focuses on the ethical dimensions of severe brain injury, disorders of consciousness, and neurotechnology. His work bridges clinical medicine, neuroscience, and philosophical ethics, with particular attention to patient rights, decision-making for non-responsive patients, and the implications of emerging neurotechnologies. He has been instrumental in developing guidelines for the assessment and treatment of disorders of consciousness, contributing to the 2018 practice guidelines published by the American Academy of Neurology. Analysis of his recent publications shows a consistent focus on disorders of consciousness, brain injury rehabilitation, neuroethics, and the intersection of disability rights with medical care. His work often addresses practical clinical challenges while maintaining a strong ethical framework, with increasing attention to the implications of artificial intelligence in neurotechnology. Dr. Fins has been particularly influential in highlighting how cognitive motor dissociation raises profound ethical questions about diagnosis, treatment, and patient rights. Medical Ethics Neuroethics Disorders of Consciousness Brain Injury and Rehabilitation Research Ethics Disability Rights and Healthcare Dr. Fins actively participated in ethics consultation services during the COVID-19 pandemic in New York City, addressing ethical challenges in resource allocation and end-of-life care. His work with the Curing Coma Campaign demonstrates his commitment to improving outcomes for patients with severe brain injuries through both research and ethical guidance. He has also contributed to cross-cultural medical ethics, examining shared perspectives of Orthodox Judaism and Islam on medical decision-making. He leads a significant research program focused on medical ethics and neuroethics, collaborating with clinicians, neuroscientists, and ethicists across multiple institutions to advance understanding of consciousness disorders and their ethical implications. His scholarship consistently bridges theoretical ethical frameworks with practical clinical challenges, making his contributions valuable to both academic discourse and bedside medicine.

• Global Mental Health
• Neglected Tropical Diseases
• Stigma Reduction
• +۵ مورد دیگر

Dr. Maya Semrau is a Senior Research Fellow in Implementation Research at Brighton and Sussex Medical School (BSMS), University of Sussex, specializing in global mental health within Neglected Tropical Disease contexts. Her work integrates physical health, mental health, and psychosocial care for people affected by podoconiosis, lymphatic filariasis, and leprosy in Ethiopia, with strong emphasis on stigma reduction and humanitarian emergency response. Her educational background includes: PhD, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (with WHO) MSc in Mental Health Service and Population Research, IoPPN, King's College London MSc in Experimental Psychology, University of Sussex BSc Honours in Human Sciences, University of Sussex Dr. Semrau's research centers on implementation science to address mental health needs in resource-limited settings, particularly through the development of the HESPER Scale for humanitarian emergencies and integration of mental health into NTD programs. Her work consistently emphasizes community involvement, capacity building, and evidence-based policy development across multiple international projects. Her publication record (2011-2019) reveals persistent focus on mental health systems strengthening in LMICs, stigma reduction, and physical-mental health integration for NTD-affected populations. She employs diverse methodologies including scale development, cross-sectional studies, systematic reviews, and implementation trials to address real-world health challenges. Dr. Semrau actively supervises PhD and MSc students at BSMS and teaches on the MSc in Global Health program. She currently leads the EnDPoINT Consortium and IMPRESS project funded by the NIHR Global Health Research Unit on NTDs, with additional involvement in WHO guideline development and the NTD NGO Network's Mental Wellbeing and Stigma Working Group. Her collaborative work spans the Emerald programme across six LMICs, the INDIGO Partnership in five countries, and multiple WHO initiatives, demonstrating extensive international engagement in mental health and NTD research through coordinated multicountry efforts.

• Schizophrenia
• Cognitive Training
• Psychosis
• +۵ مورد دیگر

Keith H Nuechterlein is a Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). He serves as Principal Investigator on multiple National Institutes of Health (NIH) funded research projects focused on schizophrenia and psychosis, including several R01 grants from the National Institute of Mental Health (NIMH). Dr. Nuechterlein's primary research interests center on cognitive impairments in schizophrenia, particularly in first-episode psychosis. His work investigates how cognitive training, aerobic exercise, and other interventions can improve cognitive function and real-world outcomes for individuals with schizophrenia. He has made significant contributions to understanding the relationship between cognitive deficits and functional outcomes, the development of cognitive assessment tools like the MATRICS Consensus Cognitive Battery, and the role of motivation in treatment engagement. His recent publications reveal a strong focus on innovative interventions for first-episode schizophrenia, with particular attention to the combination of cognitive training and aerobic exercise. His research employs diverse methodologies including clinical trials, neuroimaging, and analysis of genetic and physiological markers. A notable trend across his recent work is the examination of how intrinsic motivation influences treatment outcomes and the exploration of brain-body connections in schizophrenia pathophysiology. Dr. Nuechterlein has served as Principal Investigator on multiple major research grants totaling millions of dollars in funding, including the current R01 MH130848 ( Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode ) and R01 MH129351 ( Determining the Role of Social Reward Learning in Social Anhedonia in First-Episode Psychosis ). His research program has consistently focused on translating basic science findings into clinical interventions that improve functional outcomes for individuals with schizophrenia.

• Clinical Trials Methodology
• Bayesian Statistics
• Rare Diseases Research
• +۳ مورد دیگر

Dr. Giulia Risca is a researcher in the Department of Medicine and Surgery at the University of Milano-Bicocca, School of Medicine and Surgery. She recently completed her doctoral thesis on Bayesian methods for basket trials in rare diseases under the supervision of Professor Stefania Galimberti. Her research spans multiple domains including clinical trial methodology, hematology/oncology, and proteomics. Dr. Risca's research interests focus on developing innovative clinical trial designs for rare diseases, with particular expertise in Bayesian statistics and basket trial methodology. Her work addresses critical challenges in rare disease research where limited patient populations make traditional trial designs impractical. She has made significant contributions to understanding how information can be borrowed across sub-trials while maintaining appropriate statistical properties. Additionally, she conducts important translational research in CAR-T cell therapy for leukemia and develops diagnostic algorithms for iron metabolism disorders. Analysis of Dr. Risca's publication record reveals a strong focus on methodological innovation in clinical trials combined with impactful clinical applications. Her work demonstrates expertise in bridging statistical theory with practical clinical research needs, particularly in areas with limited patient populations. The publications span multiple disciplines but maintain a cohesive thread of methodological rigor applied to challenging clinical problems. Dr. Risca actively collaborates with clinical researchers across multiple medical specialties, contributing her statistical expertise to studies in hematology, oncology, nephrology, and ophthalmology. Her work on CARCIK-CD19 cell therapy, rare disease trial design, and diagnostic algorithms for iron overload represents significant contributions to their respective fields. She participates in multicenter studies across European institutions, demonstrating her integration into the broader research community. Dr. Risca leads research activities in biostatistics and clinical trial methodology, supervising analytical components of multiple clinical studies. Her work often involves developing and implementing sophisticated statistical approaches to address complex research questions where traditional methods are inadequate, particularly in the context of rare diseases with small sample sizes.